Valiant Laboratories Q4 FY26 Results: Announced May 14 2026 Specialty Pharma – API

Valiant Laboratories results were announced on May 14, 2026, at the company’s board meeting. Q4 FY26 PAT Rs 0.70 crore on revenue Rs 57.79 crore. Active Pharmaceutical Ingredient manufacturer focused on paracetamol and related analgesic compounds. Plant in Ankleshwar, Gujarat. API segment margins under pressure from lower realizations and competition. Recovery depends on new product launches and capacity utilisation improvement. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Valiant Laboratories Q4 FY26 Key Financial Highlights

Metric	Q4 FY26	Comparison
PAT (Net Profit)	Rs 0.70 crore	Q4 FY26
Revenue from Operations	Rs 58 crore	Q4 FY26
Ticker	VALIANTLAB	Sector: Specialty Pharma – API

Screen the best stocks on the Univest Screener.

Valiant Laboratories Performance Analysis

The company results reflect the company’s operational performance during the January to March 2026 quarter. the company results announced May 14, 2026. The company manufactures active pharmaceutical ingredients (APIs) for the domestic and export markets. Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.

The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.

Valiant Laboratories FY27 Outlook

Post Valiant, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Specialty Pharma – API space. The Valiant results demonstrate the company’s execution capabilities. Track Valiant updates on the Univest Screener for analyst views and FY27 earnings estimates.

Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.

Frequently Asked Questions on Valiant Laboratories Q4 FY26 Results

What is Valiant Laboratories Q4 FY26 PAT?

Ans. Valiant Laboratories Q4 FY26 PAT of Rs 0.70 crore (results declared May 14, 2026). Q4 FY26 PAT Rs 0.70 crore on revenue Rs 57.79 crore. Active Pharmaceutical Ingredient manufacturer focused on paracetamol and related analgesic compou.

When did Valiant Laboratories announce Q4 FY26 results?

Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.

What is the FY27 outlook for Valiant Laboratories?

Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Specialty Pharma – API sector. Track live updates on the Univest Screener.

Where can I track Valiant Laboratories Q4 FY26 live data?

Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.